Men's health in primary care: An emerging paradigm of sexual function and cardiometabolic risk

Urologic Clinics of North America

Volumn 39, Issue 1, 2012, Pages 1-23

  Miner, Martin M ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Endothelial cell dysfunction; Erectile dysfunction; Men's health; Primary care

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PLACEBO; RAMIPRIL; SEX HORMONE BINDING GLOBULIN; SILDENAFIL; TADALAFIL; TELMISARTAN; TESTOSTERONE;

ANDROGEN DEFICIENCY IN THE AGING MALE QUESTIONNAIRE; ANDROGEN THERAPY; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DIET THERAPY; DISEASE ASSOCIATION; DOCTOR PATIENT RELATION; ERECTILE DYSFUNCTION; GENERAL PRACTITIONER; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOGONADISM; KINESIOTHERAPY; MALE; MALE SEXUAL DYSFUNCTION; MEDICAL ASSESSMENT; MEDICAL SPECIALIST; MEN'S HEALTH; METABOLIC SYNDROME X; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PHYSICAL EXAMINATION; PHYSICIAN ATTITUDE; PREDICTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SEXUAL FUNCTION; SEXUAL HEALTH INVENTORY FOR MEN; SOCIAL PSYCHOLOGY; WEIGHT REDUCTION;

ADULT; AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; COMORBIDITY; ERECTILE DYSFUNCTION; HUMANS; MALE; MEN'S HEALTH; METABOLIC SYNDROME X; MIDDLE AGED; PRIMARY HEALTH CARE; PROGNOSIS; RISK ASSESSMENT; UROLOGY;

EID: 82455194917     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2011.09.003     Document Type: Review

References (125)

1. Fontanarosa P.B. Theme issue on men's health: call for papers. JAMA 2006, 295:440-441.
2. Agency for Healthcare Research and Quality. AHRQ Publication No. 06-0018. December, 2005.
3. Chandra A, Martinez GM, Mosher WD, et al. Fertility, family planning, and reproductive health of U.S. women: Data from the 2002 National Survey of Family Growth. National Center for Health Statistics. Vital Health Stat 2005;23(25):1-160.
4. Kung HC, Hoyert DL, Xu J, et al. National vital statistics report. Vol. 56, Number 10. Deaths: final data for 2005.
5. Penson D., Kreiger J.N. Men's health. Are we missing the big picture?. J Gen Intern Med 2001, 16:717-771.
6. Barton A. Men's health: a cause for concern. Nurs Stand 2000, 15(10):47-52.
7. Courtenay W.H. Constructions of masculinity and their influence on men's well being: a theory of gender and health. Soc Sci Med 2000, 50:1385-1401.
8. Rose I., Kim M.T., Dennison C.R., et al. The contexts of adherence for African Americans with high blood pressure. J Adv Nurs 2000, 32:587-594.
9. Plascencia A., Ostfield A.M., Gruber S.B. Effects of sex on differences in awareness, treatment, and control of blood pressure. Am J Prev Med 1988, 4:315-326.
10. Sandman D, Simantov E, An C. Out of touch: American men and the health care system. Commonwealth fund men's and women's health survey findings. Commonwealth Fund; 2000.
11. Thompson I.M., Tangen C.M., Goodman P.J., et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005, 294(23):2996-3002.
12. Krane R.J., Goldstein I., Saenz de Tejada I. Impotence. N Engl J Med 1989, 321:1648-1659.
13. Rosen R.C., Leiblum S.R. Erectile disorders: an overview of historical trends and clinical perspectives. Erectile disorders: assessment and treatment 1992, 3-26. Guilford, New York. R.C. Rosen, S.R. Leiblum (Eds.).
14. NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA 1993, 270(1):83-90.
15. Feldman H.A., Goldstein I., Hatzichristou D.G., et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994, 151:54.
16. Laumann E., Paik A., Rosen R.C. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999, 281(6):537-544.
17. Saigal C.S., Wessels H., Pace J., et al. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 2006, 166:207-212.
18. Seftel A.D., Sun P., Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004, 171(6 Pt 1):2341-2345.
19. Min J.K., Williams K.A., Okwuosa T.M., et al. Prediction of coronary heart disease by erectile dysfunction in men referred for nuclear stress testing. Arch Intern Med 2006, 166:201-206.
20. Grover S.A., Lowensteyn I., Kaouache M., et al. The prevalence of erectile dysfunction in the primary care setting. Arch Intern Med 2006, 166:213-219.
21. Montorsi P., Ravagnani P.M., Galli S., et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J 2006, 27(22):2632-2639.
22. Azadzoi K.M., Goldstein I. Erectile dysfunction due to atherosclerotic vascular disease: the development of an animal model. J Urol 1992, 147:1675-1681.
23. Montorsi P., Ravagnani P., Galli S., et al. Association between erectile dysfunction and coronary artery disease: matching the right target with the right test in the right patient. Eur Urol 2006, 50:721-731.
24. Jackson G., Rosen R.C., Kloner R.A., et al. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med 2006, 3:28-36.
25. Gazzaruso C., Solerte S.B., Pujia A., et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol 2008, 51(21):2040-2044.
26. Ma R.C., So W.Y., Yang X., et al. Erectile dysfunction predicts coronary artery disease in type 2 diabetics. J Am Coll Cardiol 2008, 51(21):2045-2050.
27. Hacket G. The burden and extent of comorbid conditions in patients with erectile dysfunction. Int J Clin Pract 2009, 63(8):1205-1213.
28. Inman B.A., Sauver J.L., Jacobson D.J., et al. A population-based longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009, 84(2):108-113.
29. Mykletun A., Dahl A.A., O'Leary M.P., et al. Assessment of male sexual function by the Brief Sexual Function Inventory. BJU Int 2006, 97:316-323.
30. Miner M., Kuritzky L. Erectile dysfunction: a sentinel marker for cardiovascular disease in primary care. Cleve Clin J Med 2007, 74:S30-S37.
31. Montorsi P., Montorsi F., Schulman C.C. Is erectile dysfunction the "tip of the iceberg" of a systemic vascular disorder?. Eur Urol 2003, 44(3):352-354. [editorial].
32. O'Rourke M.F., Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol 2007, 50:1-13.
33. Caretta N., Palego P., Ferlin A., et al. Resumption of spontaneous erections in selected patients affected by erectile dysfunction and various degrees of carotid wall alteration: role of tadalafil. Eur Urol 2005, 48:326-331.
34. Bohm M., Baumhakel M., Teo K., for the ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators, et al. Erectile dysfunction predicts events in high-risk patients receiving telmisatan, ramipril, or both. Circulation 2010, 121:1439-1446.
35. Billups K.L., Blank A.J., Padma-Nathan H., et al. Erectile dysfunction is a marker for cardiovascular disease: results of the Minority Health Institute Expert Advisory Panel. J Sex Med 2005, 2:40-52.
36. Alderman E.L., Corley S.D., Fisher L.D., et al. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1993, 22:1141-1154.
37. Lloyd-Jones D.M., Leip E.P., Larson M.G., et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006, 113:791-798.
38. Kostis J.B., Jackson G., Rosen R., et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005, 96(2):313-321.
39. Laumann E.O., Nicolosi A., Glasser D.B., et al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the global study of sexual attitudes and behaviors. Int J Impot Res 2005, 17:39-57.
40. de Boer B.J., Bots M.L., Lycklama A., et al. The prevalence of bother, acceptance, and need for help in men with erectile dysfunction. J Sex Med 2005, 2:445-450.
41. Korenman S.G. New insights into erectile dysfunction: a practical approach. Am J Med 1998, 105:135-144.
42. Fugl-Meyer A.R., Lodnert G., Branholm I.B., et al. On life satisfaction in male erectile dysfunction. Int J Impot Res 1997, 9:141-148.
43. Rosen R.C., Cappelleri J.C., Smith M.D., et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999, 11(6):319-326.
44. Gades N.M., Nehra A., Jacobson D.J., et al. Association between smoking and erectile dysfunction: a population-based study. Am J Epidemiol 2005, 161(4):346-351.
45. Bacon C.G., Mittleman M.A., Kawachi I., et al. A prospective study of risk factors for erectile dysfunction. J Urol 2006, 176(1):217-221.
46. Hatzichristou D., Rosen R.C., Broderick G., et al. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 2004, 1(1):49-57.
47. Wang C., Nieschlag E., Swerdloff R.S., et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009, 12:5-12.
48. Seftel A.D. Male hypogonadism. Part I: epidemiology of hypogonadism. Int J Impot Res 2006, 18(2):115-120.
49. Rhoden E.L., Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004, 350:482-492.
50. Harman S.M., Metter E.J., Tobin J.D., et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001, 86:724-731.
51. Morley J.E., Kaiser F.E., Perry H.M., et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997, 46:410-413.
52. Mulligan T., Frick M.F., Zuraw Q.C., et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006, 60(7):762-769.
53. Snyder P.J. Effects of age on testicular function and consequences of testosterone treatment. J Clin Endocrinol Metab 2001, 86:2369-2372.
54. Vermeulen A. Androgen replacement therapy in the aging male: a critical evaluation. J Clin Endocrinol Metab 2001, 86:2380-2390.
55. Bremner W.J., Vitiello M.V., Prinz P.N. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983, 56:1278-1281.
56. Bhasin S., Cunningham G.R., Hayes F., et al. Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006, 91:1995-2010.
57. Bhasin S., Cunningham G.R., Hayes F.J., et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2010, 95:2536-2559.
58. Institute of Medicine Testosterone and aging: clinical research directions. Committee on assessing the need for clinical trials of testosterone replacement therapy 2003, National Academics Press, Washington, DC.
59. Shames D., Gassman A., Handelsman H. Commentary: guideline for male testosterone therapy: aregulatory perspective. J Clin Endocrinol Metab 2007, 92(2):414-415.
60. Makhsida N., Shah J., Yan G., et al. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005, 174:827-834.
61. Dhindsa S., Prabhakar S., Sethi M., et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004, 89:5462-5468.
62. Corrales J.J., Burgo R.M., Garca-Berrocal B., et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism 2004, 53:666-672.
63. Ding E.L., Song Y., Malik V.S., et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006, 295:1288-1299.
64. Pitteloud N., Mootha V.K., Dwyer A.A., et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005, 28:1636-1642.
65. Smith M.R., Lee H., Nathan D.M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006, 91:1305-1308.
66. Kalme T., Seppala M., Qiao Q., et al. Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. J Clin Endocrinol Metab 2005, 90:1550-1556.
67. Fukui M., Kitagawa Y., Nakamura N., et al. Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care 2003, 26:1869-1873.
68. Betancourt-Albrecht M., Cunningham G.R. Hypogonadism and diabetes. Int J Impot Res 2003, 15(Suppl 4):S14-S20.
69. Tsai E.C., Matsumoto A.M., Fujimoto W.Y., et al. Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care 2004, 27:861-868.
70. Laaksonen D.E., Niskanen L., Punnonen K., et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 2003, 149:601-608.
71. Laaksonen D.E., Niskanen L., Punnonen K., et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004, 27:1036-1041.
72. Laaksonen D.E., Niskanen L., Punnonen K., et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 2005, 90:712-719.
73. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79.
74. Sullivan P.W., Morrato E.H., Ghushchyan V., et al. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. Diabetes Care 2005, 28:1599-1603.
75. Ford E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005, 28:2745-2749.
76. Niskanen L., Laaksonen D.E., Punnonen K., et al. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 2004, 6:208-215.
77. Boyanov M.A., Boneva Z., Christov V.G. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003, 6:1-7.
78. Steidle C., Schwartz S., Jacoby K., et al. the North American AA2500 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003, 88:2673-2681.
79. Liu P.Y., Yee B., Wishart S.M., et al. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab 2003, 88:3605-3613.
80. Malkin C.J., Pugh P.J., Jones R.D., et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004, 89:3313-3318.
81. Kapoor D., Goodwin E., Channer K.S., et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006, 154:899-906.
82. Pagotto U., Gambineri A., Pelusi C., et al. Testosterone replacement therapy restores normal ghrelin in hypogonadal men. J Clin Endocrinol Metab 2003, 88:4139-4143.
83. Yeap B.B., Chubb S.A., Hyde Z., et al. Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health In Men Study. Eur J Endocrinol 2009, 161:591-598.
84. Stellato R.K., Feldman H.A., Hamdy O., et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care 2000, 23:490-494.
85. Selvin E., Feinleib M., Zhang L., et al. Androgens and diabetes in men. Diabetes Care 2007, 30:234-238.
86. Pitteloud N., Hardin M., Dwyer A.A., et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005, 90:2636-2641.
87. Oh J.Y., Barrett-Connor E., Wedick N.M., et al. Rancho Bernardo Study. Endogenous sex hormones and the development of type 2 diabetes in older men and women; the Rancho Bernardo study. Diabetes Care 2002, 25:55-60.
88. Kupelian V., Shabsigh R., Araujo A.B., et al. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol 2006, 176:201-206.
89. Esposito K., Giugliano F., Di Palo C., et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004, 291(24):2978-2984.
90. Traish A.M., Guay A., Feeley R., et al. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009, 30:10-22.
91. Traish A.M., Saad F., Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 2009, 30:23-32.
92. Traish A.M., Saad F., Feeley R.J., et al. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 2009, 30:477-494.
93. Hak A.E., Witteman J.C., de Jong F.H., et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam Study. J Clin Endocrinol Metab 2002, 87:3632-3639.
94. Phillips G., Pinkernell B., Jing T. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994, 14:701-706.
95. Srinivas-Shankar U., Roberts S.A., Connolly M.J., et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010, 95:639-650.
96. van Pottelbergh I., Braeckman L., De Bacquer D., et al. Potential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 2003, 166:95-102.
97. Makinen J.I., Perheentupa A., Irjala K., et al. Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis 2008, 197:688-693.
98. Makinen J., Jarvisalo M., Pollanen P., et al. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol 2005, 45:1603-1608.
99. Simon D., Charles M.A., Nahoul K., et al. Association between plasma testosterone and cardiovascular risk factors in healthy adult men: the Telecom study. J Clin Endocrinol Metab 1997, 82:682-685.
100. Allan C.A., Strauss B.J., Burger H.G., et al. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 2008, 93:139-146.
101. Basaria S., Muller D.C., Carducci M.A., et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006, 106:581-588.
102. Haidar A., Yassin A., Saad F., et al. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male 2007, 10:189-196.
103. Yialamas M.A., Dwyer A.A., Hanley E., et al. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007, 92:4254-4259.
104. Traish A.M., Feeley R.J., Guay A. Mechanisms of obesity and related pathologies: androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. FEBS J 2009, 276:5755-5767.
105. Fukui M., Kitagawa Y., Ose H., et al. Role of endogenous androgen against insulin resistance and atherosclerosis in men with type 2 diabetes. Curr Diabetes Rev 2007, 3:25-31.
106. Akishita M., Hashimoto M., Ohike Y., et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res 2007, 30:1029-1034.
107. Akishita M., Hashimoto M., Ohike Y., et al. Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis 2009, 210:232-236.
108. Nettleship J.E., Pugh P.J., Channer K.S., et al. Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. Horm Metab Res 2007, 39:366-371.
109. Traish A.M., Abdou R., Kypreos K.E. Androgen deficiency and atherosclerosis: the lipid link. Vascul Pharmacol 2009, 51:303-313.
110. Allan C.A., McLachan R.I. Age related changes in testosterone and the role of replacement therapy in older men. Clin Endocrinol 2004, 60:653-670.
111. Wang C., Swerdloff R.S., Iranmanesh A., et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000, 85:2839-2853.
112. Heufelder A.E., Saad F., Bunck M.C., et al. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009, 30:726-733.
113. Caminiti G., Volterrani M., Iellamo F., et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure adouble-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009, 54:919-927.
114. Shores M.M., Matsumoto A.M., Sloan K.L., et al. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006, 166:1660-1665.
115. Khaw K.T., Dowsett M., Folkerd E., et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007, 116:2694-2701.
116. Laughlin G.A., Barrett-Connor E., Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008, 93:68-75.
117. Basaria S., Coviello A.D., Travison T.G., et al. Adverse events associated with testosterone administration. N Engl J Med 2010, 363(2):109-122.
118. Lorenzo C., Williams K., Hunt K.J., et al. The National Cholesterol Education program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007, 30:8-13.
119. Esposito K., Giugliano F., Martedi E., et al. High proportions of erectile dysfunction in men with metabolic syndrome. Diabetes Care 2005, 28:1201-1203.
120. Guembe M.J., Toledo E., Barba J., et al. Association between metabolic syndrome or its components and asymptomatic cardiovascular disease in the RIVANA-study. Atherosclerosis 2010, 211(2):612-617.
121. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
122. Anawalt B.D. Guidelines for testosterone therapy for men: how to avoid a mad (T)ea party by getting personal. J Clin Endocrinol Metab 2010, 95:2614-2617. [editorial].
123. McLachlan R.I. Certainly more guidelines than rules. J Clin Endocrinol Metab 2010, 95:2610-2613. [editorial].
124. Morley J.E., Charlton E., Patrick P., et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000, 49:1239-1242.
125. Richardson D., Vinik A. Etiology and treatment of erectile failure in diabetes mellitus. Curr Diab Rep 2002, 2:501.